AcelRx Pharmaceuticals In... (ACRX)
NASDAQ: ACRX
· Real-Time Price · USD
0.86
0.06 (7.50%)
At close: Jan 09, 2024, 10:00 PM
AcelRx Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|
| Contract and Other Collaboration Revenue | n/a | 1.81M | 1.11M | 459K |
| Contract and Other Collaboration Revenue Growth | -100.00% | +63.04% | +142.27% | n/a |
| Contract and Other Revenue Revenue | n/a | 6K | n/a | 43K |
| Contract and Other Revenue Revenue Growth | -100.00% | n/a | n/a | n/a |
| DSUVIA Revenue | 1.59M | 735K | n/a | 377K |
| DSUVIA Revenue Growth | +116.05% | n/a | n/a | n/a |
| DZUVEO Revenue | 183K | 1.7M | n/a | 312K |
| DZUVEO Revenue Growth | -89.21% | n/a | n/a | n/a |
| License Revenue | n/a | 83K | n/a | 1.83M |
| License Revenue Growth | -100.00% | n/a | n/a | n/a |
| Non-cash Royalty Revenue | n/a | 1M | n/a | 104K |
| Non-cash Royalty Revenue Growth | -100.00% | n/a | n/a | n/a |
| Product Revenue | 1.77M | 28K | n/a | 1.45M |
| Product Revenue Growth | +6225.00% | n/a | n/a | n/a |
| Royalty Revenue | n/a | 270K | n/a | n/a |
| Royalty Revenue Growth | -100.00% | n/a | n/a | n/a |
| ZALVISO Revenue | n/a | n/a | n/a | n/a |
| ZALVISO Revenue Growth | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 |
|---|---|---|---|---|
| Australia Revenue | 166M | 166M | 20M | 20M |
| Australia Revenue Growth | 0.00% | +730.00% | 0.00% | n/a |
| Europe Revenue | 20M | 20M | n/a | n/a |
| Europe Revenue Growth | 0.00% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.77M | 665K | 1.7M | 2.36M | 2.8M | 2.79M | 2.25M | 2.67M | 4.28M | 3.69M | 5.26M | 6.82M | 7.34M | 9.49M | 8.64M | 8.69M | 7.64M | 7.85M | 7.6M | 7.58M | 13.31M | 12.79M | 10.94M | 11.33M | 9.98M | 7.65M | 5.19M | 3.94M | 3.98M | 3.91M | 4.41M | 4.16M | 4.14M | 4.08M | 4.14M | 3.6M | 3.78M | 4.02M | 2.93M | 2.73M | 4.52M |
| Selling, General, and Administrative Revenue Growth | +166.77% | -60.79% | -28.17% | -15.80% | +0.32% | +24.33% | -15.81% | -37.63% | +16.05% | -29.89% | -22.87% | -7.03% | -22.68% | +9.84% | -0.62% | +13.74% | -2.57% | +3.26% | +0.30% | -43.09% | +4.11% | +16.92% | -3.47% | +13.56% | +30.44% | +47.42% | +31.54% | -1.03% | +1.94% | -11.28% | +6.02% | +0.43% | +1.47% | -1.62% | +15.23% | -4.77% | -5.97% | +37.10% | +7.13% | -39.50% | n/a |
| Research and Development Revenue | 1.17M | 2.94M | 2.05M | 1.91M | 1.43M | 1.77M | 1.18M | 1.55M | 1.05M | 1.03M | 1.31M | 1.54M | 1.31M | 674K | 1.42M | 724K | 969K | 836K | 956K | 813K | 1.41M | 1.06M | 1.06M | 1.16M | 1.38M | 2.7M | 3.64M | 3.28M | 3.51M | 3.68M | 3.91M | 4.9M | 6.92M | 6.33M | 4.62M | 6.28M | 4.17M | 3.48M | 5.39M | 7.31M | 6.31M |
| Research and Development Revenue Growth | -60.25% | +43.25% | +7.54% | +33.22% | -18.99% | +50.17% | -24.10% | +48.23% | +2.05% | -21.56% | -15.28% | +17.41% | +95.10% | -52.40% | +95.58% | -25.28% | +15.91% | -12.55% | +17.59% | -42.42% | +32.83% | +0.47% | -9.03% | -15.54% | -49.08% | -25.76% | +11.10% | -6.69% | -4.43% | -6.06% | -20.16% | -29.17% | +9.24% | +37.19% | -26.48% | +50.56% | +19.89% | -35.49% | -26.22% | +15.92% | n/a |